All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
VivoCAR™ Anti-c-Met (A1) h(CD28-41BB-CD3z) CAR saRNA utilizes a high-efficiency saRNA backbone to express the A1 clone. In the landscape of in vivo CAR-T therapy, the A1 clone is essential for its ability to target the c-Met receptor, which is often upregulated in metastatic solid tumors. The saRNA platform achieves a biological magnification effect, where a minimal dose leads to robust CAR expression, ensuring that reprogrammed T cells can effectively engage and eliminate c-Met positive cells even in the presence of competing HGF ligands.
There are currently no customer reviews or questions for VivoCAR™ Anti-c-Met (A1) h(CD28-41BB-CD3z) CAR saRNA (XS-0326-XU29). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION